Immunosuppressive therapy and COVID ‐19 infection in patients with NMOSD

DiscussionImmunosuppressant-treated patients with NMOSD have a similar risk of COVID-19 infection as the general population, but the disease duration is shorter and the clinical symptoms are less severe. Among our NMOSD patients who received hUC-MSCs treatment, COVID-19 outcomes were favorable, with no increased risk of severe COVID-19. Prospective studies on immunotherapies are needed to help determine best treatment practices.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: SHORT REPORT Source Type: research